FDA approves Purdue's abuse-deterrent opioid Targiniq ER for pain-management

The US Food and Drug Administration has approved privately-held USA-based Purdue Pharma’s abuse-deterrent opioid analgesic Targiniq ER (oxycodone/naloxone) for the treatment of severe pain requiring long-term opioid treatment for which other therapies are inadequate.

The FDA has called prescription drug abuse a ‘public health crisis,’ which means abuse-deterrent solutions are now particularly necessary.

Targiniq ER was evaluated for safety and effectiveness in a trial of 601 people with chronic low back pain, and a safety database included more than 3,000 people treated with it.